Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027

뉴스 본문을 불러오고 있어요.

Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027 | 웨이프 WAPE

Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027

기사 요약

관련 종목

댓글 —